US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

3.73

-0.1700-4.36%

Post-market: 3.730.00000.00%16:10 EDT

Volume:105.31K

Turnover:396.25K

Market Cap:9.23M

PE:-0.30

High:3.88

Open:3.75

Low:3.71

Close:3.90

52wk High:137.16

52wk Low:2.12

Shares:2.47M

Float Shares:2.02M

Volume Ratio:0.50

T/O Rate:5.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-12.3857

EPS(LYR):-40.4307

ROE:-503.98%

ROA:-64.67%

PB:0.71

PE(LYR):-0.09

Loading ...

Overview Company News Filings

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM

Super League Enterprise Q1 Adj. EPS $(0.98) Beats $(2.08) Estimate, Sales $3.003M Beat $2.813M Estimate

Benzinga Earnings

Super League Enterprise Q1 revenue rises, gross margin improves

Super League Enterprise Q1 Revenue USD 3 Million

THOMSON REUTERS

Super League Reports First Quarter 2026 Financial Results, Advancing Transition From Corporate Restructuring to Operational Execution

THOMSON REUTERS

Press Release: Super League Reports First Quarter 2026 Financial Results, Advancing Transition from Corporate Restructuring to Operational Execution

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Super League Enterprise Inc expected to post a loss of $2.08 a share - Earnings Preview

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Super League Enterprise director Robert Kalutkiewicz files initial beneficial ownership statement

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Super League names Robert Kalutkiewicz to board as Mark Jung steps down

Super League closes acquisition of Misfits Ads Division from Misfits Gaming Group

LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis

Super League sets first-quarter 2026 earnings release, hosts results webinar

Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/SLE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":3.73,"timestamp":1788292800000,"preClose":3.9,"halted":0,"volume":105313,"hourTrading":{"tag":"盘后","latestPrice":3.73,"preClose":3.73,"latestTime":"16:10 EDT","volume":10,"amount":37.3,"timestamp":1788293404570,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.043589743589743574,"floatShares":2020495,"shares":2473200,"eps":-12.385672,"marketStatus":"Post-Mkt","change":-0.17,"latestTime":"09-01 16:12:15 EDT","open":3.75,"high":3.875,"low":3.71,"amount":396250.5358305,"amplitude":0.042308,"askPrice":3.95,"askSize":500,"bidPrice":3.76,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-12.385672,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":3.9,"preHourTrading":{"tag":"盘前","latestPrice":3.67,"preClose":3.9,"latestTime":"09:28 EDT","volume":8372,"amount":31417.791095599998,"timestamp":1788269288082,"change":-0.23,"changeRate":-0.058974,"amplitude":0.046154},"postHourTrading":{"tag":"盘后","latestPrice":3.73,"preClose":3.73,"latestTime":"16:10 EDT","volume":10,"amount":37.3,"timestamp":1788293404570,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.502839},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":2020495,"roa":"-64.67%","roe":"-503.98%","lyrEps":-40.430703,"volumeRatio":0.502839,"shares":2473200,"dividePrice":0,"high":3.875,"amplitude":0.042308,"preClose":3.9,"low":3.71,"week52Low":2.12,"pbRate":"0.71","psRate":"0.79","week52High":137.16,"institutionHeld":0,"latestPrice":3.73,"committee":-0.976285,"eps":-12.385672,"divideRate":0,"volume":105313,"delay":0,"ttmEps":-12.385672,"open":3.75,"prevYearClose":7.326,"prevWeekClose":3.86,"prevMonthClose":3.9,"prevQuarterClose":2.97,"fiveDayClose":3.96,"twentyDayClose":2.69,"sixtyDayClose":3.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"SLE","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-2.7},{"market":"US","date":"2026-05-15","symbol":"SLE","fiscalQuarterEnding":"2026/03","expectedEps":-2.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-1.77},{"market":"US","date":"2026-03-27","symbol":"SLE","fiscalQuarterEnding":"2025/12","expectedEps":-3.12,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774584000000,"reportTimeType":"pre","actualEps":-9.44},{"market":"US","date":"2026-01-23","symbol":"SLE","defaultRemindTime":1769178600000,"type":"split","dateTimestamp":1769144400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-11-13","symbol":"SLE","fiscalQuarterEnding":"2025/09","expectedEps":-2.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-2.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1782964800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2026-08-31","current":-0.301154,"percent":0.335655,"low":-0.738945,"twenty":-0.346896,"median":-0.267958,"eighty":-0.211416,"high":-0.044016,"avg":-0.281313,"sd":0.11574,"marketCap":6543163},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959},{"date":"2025-08-15","current":-0.231876,"twenty":-0.33606,"median":-0.271353,"eighty":-0.213354,"marketCap":3618418},{"date":"2025-08-22","current":-0.221928,"twenty":-0.335323,"median":-0.269787,"eighty":-0.212104,"marketCap":3535981},{"date":"2025-08-29","current":-0.23749,"twenty":-0.333566,"median":-0.269388,"eighty":-0.213354,"marketCap":3783930},{"date":"2025-09-05","current":-0.192157,"twenty":-0.332345,"median":-0.269014,"eighty":-0.213084,"marketCap":3061642},{"date":"2025-09-12","current":-0.207719,"twenty":-0.332042,"median":-0.268116,"eighty":-0.210012,"marketCap":3309592},{"date":"2025-09-19","current":-0.247639,"twenty":-0.331721,"median":-0.267958,"eighty":-0.20982,"marketCap":3945637},{"date":"2025-09-26","current":-0.362878,"twenty":-0.332345,"median":-0.267958,"eighty":-0.210012,"marketCap":5781732},{"date":"2025-10-03","current":-0.272683,"twenty":-0.334082,"median":-0.268394,"eighty":-0.210038,"marketCap":4344654},{"date":"2025-10-10","current":-0.24891,"twenty":-0.332345,"median":-0.268116,"eighty":-0.210567,"marketCap":3965889},{"date":"2025-10-17","current":-0.321134,"twenty":-0.33627,"median":-0.269014,"eighty":-0.211856,"marketCap":5116629},{"date":"2025-10-24","current":-0.188157,"twenty":-0.335429,"median":-0.268704,"eighty":-0.211856,"marketCap":2997912},{"date":"2025-10-31","current":-0.131167,"twenty":-0.334082,"median":-0.267958,"eighty":-0.20982,"marketCap":2089890},{"date":"2025-11-07","current":-0.105839,"twenty":-0.332345,"median":-0.267719,"eighty":-0.208727,"marketCap":1686325},{"date":"2025-11-14","current":-0.110362,"twenty":-0.332042,"median":-0.267321,"eighty":-0.207583,"marketCap":1758390},{"date":"2025-11-21","current":-0.081028,"twenty":-0.331721,"median":-0.26512,"eighty":-0.206427,"marketCap":1285354},{"date":"2025-11-28","current":-0.659255,"twenty":-0.334597,"median":-0.266863,"eighty":-0.206708,"marketCap":10457765},{"date":"2025-12-05","current":-0.720254,"twenty":-0.337177,"median":-0.26748,"eighty":-0.207472,"marketCap":11425396},{"date":"2025-12-12","current":-0.614194,"twenty":-0.34219,"median":-0.267958,"eighty":-0.207492,"marketCap":9742959},{"date":"2025-12-19","current":-0.474574,"twenty":-0.347254,"median":-0.268394,"eighty":-0.207537,"marketCap":7528174},{"date":"2025-12-26","current":-0.4608,"twenty":-0.349022,"median":-0.269014,"eighty":-0.207719,"marketCap":7309663},{"date":"2026-01-02","current":-0.447318,"twenty":-0.351152,"median":-0.26966,"eighty":-0.207719,"marketCap":7095801},{"date":"2026-01-09","current":-0.503223,"twenty":-0.354793,"median":-0.269873,"eighty":-0.208261,"marketCap":7982631},{"date":"2026-01-16","current":-0.526743,"twenty":-0.360917,"median":-0.271353,"eighty":-0.208641,"marketCap":8355727},{"date":"2026-01-23","current":-0.388481,"twenty":-0.368101,"median":-0.272683,"eighty":-0.20874,"marketCap":6162476},{"date":"2026-01-30","current":-0.377954,"twenty":-0.369864,"median":-0.273838,"eighty":-0.208765,"marketCap":5995491},{"date":"2026-02-06","current":-0.254616,"twenty":-0.369341,"median":-0.274166,"eighty":-0.209154,"marketCap":4038966},{"date":"2026-02-13","current":-0.250952,"twenty":-0.368944,"median":-0.274262,"eighty":-0.209588,"marketCap":3980851},{"date":"2026-02-20","current":-0.244846,"twenty":-0.368353,"median":-0.273838,"eighty":-0.20982,"marketCap":3883993},{"date":"2026-02-27","current":-0.219812,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"marketCap":3486877},{"date":"2026-03-06","current":-0.285756,"twenty":-0.365648,"median":-0.271783,"eighty":-0.20982,"marketCap":4532940},{"date":"2026-03-13","current":-0.266522,"twenty":-0.361898,"median":-0.272212,"eighty":-0.210012,"marketCap":4227838},{"date":"2026-03-20","current":-0.285756,"twenty":-0.360355,"median":-0.272267,"eighty":-0.210038,"marketCap":4532940},{"date":"2026-03-27","current":-0.254616,"twenty":-0.358486,"median":-0.271712,"eighty":-0.210567,"marketCap":4038966},{"date":"2026-04-02","current":-0.208821,"twenty":-0.355643,"median":-0.27114,"eighty":-0.210302,"marketCap":3312533},{"date":"2026-04-10","current":-0.260127,"twenty":-0.354839,"median":-0.269787,"eighty":-0.210302,"marketCap":5389056},{"date":"2026-04-17","current":-0.281981,"twenty":-0.354827,"median":-0.26986,"eighty":-0.211608,"marketCap":5841796},{"date":"2026-04-24","current":-0.268594,"twenty":-0.354771,"median":-0.270513,"eighty":-0.212842,"marketCap":5564456},{"date":"2026-05-01","current":-0.267882,"twenty":-0.354343,"median":-0.269886,"eighty":-0.213819,"marketCap":5549706},{"date":"2026-05-08","current":-0.295375,"twenty":-0.352599,"median":-0.271247,"eighty":-0.213857,"marketCap":6119281},{"date":"2026-05-15","current":-0.286915,"twenty":-0.351648,"median":-0.272111,"eighty":-0.213857,"marketCap":5944027},{"date":"2026-05-22","current":-0.634562,"twenty":-0.354827,"median":-0.272503,"eighty":-0.213857,"marketCap":13032642},{"date":"2026-05-29","current":-0.249501,"twenty":-0.354781,"median":-0.272503,"eighty":-0.213857,"marketCap":5124247},{"date":"2026-06-05","current":-0.248769,"twenty":-0.35473,"median":-0.272212,"eighty":-0.214067,"marketCap":5109220},{"date":"2026-06-12","current":-0.241452,"twenty":-0.352795,"median":-0.271911,"eighty":-0.214067,"marketCap":4958949},{"date":"2026-06-18","current":-0.230477,"twenty":-0.35201,"median":-0.271247,"eighty":-0.214405,"marketCap":4733542},{"date":"2026-06-26","current":-0.225356,"twenty":-0.351152,"median":-0.269886,"eighty":-0.214489,"marketCap":4628352},{"date":"2026-07-02","current":-0.229746,"twenty":-0.35011,"median":-0.269715,"eighty":-0.214549,"marketCap":4718515},{"date":"2026-07-10","current":-0.220234,"twenty":-0.349224,"median":-0.269201,"eighty":-0.214489,"marketCap":4523163},{"date":"2026-07-17","current":-0.207795,"twenty":-0.349022,"median":-0.268594,"eighty":-0.214067,"marketCap":4267702},{"date":"2026-07-24","current":-0.19682,"twenty":-0.348987,"median":-0.268161,"eighty":-0.213857,"marketCap":4042295},{"date":"2026-07-31","current":-0.20121,"twenty":-0.348468,"median":-0.267958,"eighty":-0.213493,"marketCap":4132458},{"date":"2026-08-07","current":-0.202674,"twenty":-0.34754,"median":-0.267882,"eighty":-0.210977,"marketCap":4162512},{"date":"2026-08-14","current":-0.245842,"twenty":-0.347244,"median":-0.2674,"eighty":-0.211398,"marketCap":5049112},{"date":"2026-08-21","current":-0.293824,"twenty":-0.347244,"median":-0.26748,"eighty":-0.210977,"marketCap":6506742},{"date":"2026-08-28","current":-0.291642,"twenty":-0.347002,"median":-0.26792,"eighty":-0.211398,"marketCap":6458407},{"date":"2026-08-31","current":-0.295469,"twenty":-0.346896,"median":-0.267958,"eighty":-0.211416,"marketCap":6543163}],"updateTime":1788293533984},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635080624","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2635080624","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635080624?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:34","pubTimestamp":1778852062,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nAQN2LZ6ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081308","title":"Super League Enterprise Q1 Adj. EPS $(0.98) Beats $(2.08) Estimate, Sales $3.003M Beat $2.813M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081308","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081308?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:50","pubTimestamp":1778845838,"startTime":"0","endTime":"0","summary":"Super League Enterprise (NASDAQ:SLE) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(2.08) by 52.88 percent. This is a 99.07 percent increase over losses of $(105.60) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52592661/super-league-enterprise-q1-adj-eps-0-98-beats-2-08-estimate-sales-3-003m-beat-2-813m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089735","title":"Super League Enterprise Q1 revenue rises, gross margin improves","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089735","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089735?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:41","pubTimestamp":1778845312,"startTime":"0","endTime":"0","summary":"Super League Enterprise Q1 revenue rises, gross margin improvesOverviewUS audience intelligence firm's Q1 revenue grew yr/yr, gross margin improved to 36%Company ended Q1 with $11.4 mln in cash and in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL1N41S0HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089976","title":"Super League Enterprise Q1 Revenue USD 3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089976?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:32","pubTimestamp":1778844779,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX32AEAF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089920","title":"Super League Reports First Quarter 2026 Financial Results, Advancing Transition From Corporate Restructuring to Operational Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089920","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089920?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUASQDJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635910089","title":"Press Release: Super League Reports First Quarter 2026 Financial Results, Advancing Transition from Corporate Restructuring to Operational Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2635910089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635910089?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"Gross revenue growth and improved gross margin reflects strengthening operating momentum. Strong cash position and expanded operating capabilities support path to EBITDA profitability by fiscal year-end. SANTA MONICA, Calif., May 15, 2026  -- Super League  , an audience intelligence and media activation company trusted by global brands to reach and engage people who play video games across the digital advertising landscape, today announced financial results for the first quarter ended March 31, 2026, and provided a business update following the recent closing of its acquisition of the Misfits Ads Business.Gross revenue for Q1 2026 increased to $3.0 million, compared to $2.7 million in the prior-year first quarter. Gross margin improved to 36% in Q1 2026, compared to 32% in Q4 2025, reflecting continued improvement in the quality and structure of the Company's revenue mix and delivery model.\"We continue to advance a more connected and strategically integrated business through the combin","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635171647","title":"Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2635171647","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635171647?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761800,"startTime":"0","endTime":"0","summary":"Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294940/0/en/Vor-Bio-Announces-Publication-of-Interim-Analysis-of-TELIGAN-a-China-Phase-3-Trial-of-Telitacicept-in-IgA-Nephropathy-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","RA","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635173719","title":"Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635173719","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635173719?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756400,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., May  14, 2026  (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294750/0/en/Climb-Bio-to-Present-New-Budoprutug-Clinical-Data-at-European-Hematology-Association-EHA-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","BK4199","ITP","SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635621733","title":"Super League Enterprise Inc  expected to post a loss of $2.08 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635621733","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635621733?lang=en_us&edition=fundamental","pubTime":"2026-05-13 22:21","pubTimestamp":1778682074,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc  expected to post a loss of $2.08 a share - Earnings Preview Super League Enterprise Inc SLE.OQ SLE.O is expected to  show a rise in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q207:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782088","title":"Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782088?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293996/24675/en/Fate-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1221951046.USD","LU2506951875.HKD","LU0912757837.SGD","LU0949170772.SGD","SITC","LU1894683348.USD","KO","IE00BLSP4239.USD","LU1732799900.SGD","LU1868836591.USD","LU1920062954.HKD","LU2125154778.USD","LU0795875086.SGD","BK4504","SG9999014567.USD","CMC","IE00BVYPNW00.USD","BK4139","LU0170899867.USD","LU1868837136.USD","IE00B3PB1722.GBP","LU0289960550.SGD","BK4533","LU0971096721.USD","SG9999011175.SGD","BK4581","LU2237443465.HKD","SG9999014559.SGD","LU0545039389.USD","LU0882574139.USD","LU2347655156.SGD","LU2746668974.SGD","IIM","LU1670711123.USD","CAR","LU2125154935.USD","RA","SLE","LU0098860793.USD","LU1920063259.USD","IE00BBT3K403.USD","LU0096364046.USD","LU2133065610.SGD","BK4080","IND","LU1894683264.USD","FATE","BK4559","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782086","title":"Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782086","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782086?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294002/0/en/Vor-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","RA","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200456","title":"Press Release: Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200456","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635200456?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:00","pubTimestamp":1778666400,"startTime":"0","endTime":"0","summary":"-- Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results --. -- Obexelimab Phase 3 INDIGO IgG4-RD trial results accepted for oral presentation at EULAR 2026 --. -- Obexelimab global Phase 2 SunStone SLE trial enrollment complete; topline results expected in Q4 2026 --. -- First subject dosed in Phase 1 trial of ZB021 ; initial clinical data expected by year-end --. -- Orelabrutinib global Phase 3 PriMroSe trial in patients with PPMS and global Phase 3 Monarch trial in patients with naSPMS ongoing --. -- Completed public offerings and entered into debt financing; cash runway extended into 2029 --. WALTHAM, Mass., May 13, 2026  -- Zenas BioPharma, Inc.  , a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today reported","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAA","BK4588","BK4139","BK4215","SLE","BK4077","ZBIO","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633732453","title":"Super League Enterprise director Robert Kalutkiewicz files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633732453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633732453?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:43","pubTimestamp":1778240620,"startTime":"0","endTime":"0","summary":"Super League Enterprise filed an initial beneficial ownership statement naming Robert Kalutkiewicz as a director, dated May 6.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL9ZBzpw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633453731","title":"Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453731","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453731?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289829/0/en/Climb-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","ITP","LU1169589451.USD","PD","PK","SLE","BK4199","BK4077","BK4218","BK4023","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145383","title":"Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145383","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145383?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289800/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","RA","CGEM","BK4139","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633113571","title":"Super League names Robert Kalutkiewicz to board as Mark Jung steps down","url":"https://stock-news.laohu8.com/highlight/detail?id=2633113571","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633113571?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:02","pubTimestamp":1778072538,"startTime":"0","endTime":"0","summary":"Super League named Robert Kalutkiewicz to board, effective today, as condition of closing acquisition of Misfits Ads Division.Kalutkiewicz serves as senior vice president of corporate development, strategy, strategic investments at E.W. Scripps.Justin Stefanovic joined management as senior vice president of business development and platform strategy, coming from senior vice president role at Misfits Gaming Group.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the inform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL8FcbLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4125","BK4077","SSP","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633135089","title":"Super League closes acquisition of Misfits Ads Division from Misfits Gaming Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2633135089","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633135089?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:02","pubTimestamp":1778072527,"startTime":"0","endTime":"0","summary":"Super League closed its acquisition of Misfits Gaming Group’s Misfits Ads Division, adding a programmatic advertising business and proprietary rewarded-video monetization technology.Contribution to financial results expected to begin in Q2, supporting a target of cash-based EBITDA profitability by year end.Deal expands scale in gaming advertising, targeting an under-monetized market where US gaming ad spend is near $10 billion versus more than $150 billion across social and streaming.Transaction includes a preferred commercial brand partnership with Misfits Gaming Group covering brand integrations across Roblox games reaching more than 100 million monthly active users.Board changes tied to closing include Robert Kalutkiewicz joining as a director, replacing Mark Jung; former Misfits executive Justin Stefanovic joined as SVP of business development and platform strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL3Fm7Lt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0786609619.USD","BK4554","RBLX","LU1988902786.USD","IE0001KFT4U8.USD","RBLU","BK4565","LU2264538146.SGD","BK4547","LU2543165471.USD","BK4588","BK4585","BK4077","LU1861558580.USD","LU1064131342.USD","BK4535","BK4551","SLE","BK4085","RBLY","BK4598","LU0348723411.USD","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972146","title":"LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972146","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972146?lang=en_us&edition=fundamental","pubTime":"2026-05-06 10:57","pubTimestamp":1778036220,"startTime":"0","endTime":"0","summary":"NANJING, China, May  05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (\"Leads Biolabs\"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASD","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288455/0/en/LBL-047-Prioritized-for-Clinical-Development-in-Sj%C3%B6gren-s-Disease-Systemic-Lupus-Erythematosus-and-Dermatomyositis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4546","DNTH","SLE","TACI","BK4139","DM","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633146924","title":"Super League sets first-quarter 2026 earnings release, hosts results webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2633146924","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633146924?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:45","pubTimestamp":1778013905,"startTime":"0","endTime":"0","summary":"Super League to release first-quarter 2026 results before market open May 15, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL7GSTxT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4077","LU0314104364.USD","BK4588","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SLE","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014005.SGD","LU2095319765.USD","NDAQ","SG9999014021.USD","IE00B64PRP62.GBP","BK4112","IE00BN0W2T93.GBP","BK4585","LU2210150020.SGD","IE00BN0W2W23.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633251929","title":"Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633251929","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633251929?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:01","pubTimestamp":1778011260,"startTime":"0","endTime":"0","summary":"Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A. Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis. Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis  on track to initiate in mid-2026; top-line results anticipated in 2H'28. Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy  ongoing; top-line results on track for Q4'26. Building a rheumatology franchise around DNTH212 with first three priority indications of Sjgren's Disease , Systemic Lupus Erythematosus , and Dermatomyositis . Further strengthened the balance sheet with approximately $719 million in gross proceeds from an underwritten public offering of common stock and pre-funded warrants. Approximately $1.2 billion of cash as of March 31, 2026 provides expected runway into 2030. NEW YORK and ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DM","AAN","DNTH","BK4139","BK4007","BK4546","BK4178","BK4539","SLE","BK4077","LENZ","BK4161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":113,"code":"91000000","status":"200"}]}}